Back to People

Alexander Munoz, M.D.

Associate

About

Alexander Munoz is an Associate at F-Prime Capital and works across the life sciences sub-sectors including therapeutics and medical technology. Prior to joining F-Prime, Alexander was a consultant at Boston Consulting Group, where he focused on biopharma diligence and commercial go-to-market strategy.

Alexander holds an M.D. from the Harvard-MIT Health Sciences & Technology (HST) program and an A.B. in applied mathematics and computer science from Harvard University.

  • AvenCell derives its name from the French word “avenir” to reflect the aim to be the FUTURE of cell therapy. AvenCell is building a truly transformative cell therapy company that targets difficult-to-treat cancers, with its lead programs focusing on acute myeloid leukemia (AML) and additional programs targeting other hematological malignancies. AvenCell was formed with the goal to create truly allogeneic cells that persist as long or longer than autologous therapies and develop a universal and switchable construct that allows complete control and target redirection of T cells after they are infused into a patient. Integration of these two platforms allows for complete separation of the manufacturing of cells from ultimate patient and cancer target, thus providing significant scalability potential at orders of magnitude more efficient than current approaches.

    Learn more at avencell.com.

  • nChroma Bio is a pioneering biotechnology company redefining the future of in vivo targeted genetic medicine to treat a wide array of diseases and bring cures to patients. The company’s integrated product engine tackles significant limitations of existing genetic medicine approaches by enabling safe, precise and specific in vivo delivery. nChroma’s near clinical-stage development candidate, CRMA-1001, is a liver-targeted therapy in development as a potential functional cure for chronic hepatitis B and hepatitis D that leverages the power of epigenetics, nature’s innate mechanism for gene regulation. Guided by a world-class team at the forefront of genetic medicine, founded by renowned pioneers in the field, and supported by top-tier investors, the company is uniquely positioned to deliver groundbreaking therapies with programmable tissue specificity, unlocking highly potent, durable and targeted gene regulation for the liver and beyond. Learn more at nchromabio.com.

  • RhyGaze is a cutting-edge biotechnology company based in Basel, Switzerland, and Philadelphia, Pa., USA, focused on developing gene therapies for retinal diseases causing blindness. Founded on pioneering research from the Institute of Molecular and Clinical Ophthalmology Basel (IOB), RhyGaze aims to restore vision and transform the lives of patients worldwide. IOB scientists Drs. Botond Roska, Bence György and Charles Gubser are the scientific founders of RhyGaze. The name RhyGaze derives from the Basel-German word for the Rhein (Rhy), on the banks of which the IOB is located. Learn more at www.rhygaze.com.